{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:12:33Z","timestamp":1790993553435,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.abd.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T13:11:25Z","timestamp":1700313085000},"page":"196-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical profile of vitiligo patients and relationship with immuno-inflammatory markers"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4210-4997","authenticated-orcid":false,"given":"Marta Regina Machado","family":"Mascarenhas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0111-8495","authenticated-orcid":false,"given":"Mariana de Castro","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-528X","authenticated-orcid":false,"given":"Luise Fonseca de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5067-3957","authenticated-orcid":false,"given":"Andr\u00e9a Santos","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1894-6171","authenticated-orcid":false,"given":"Paulo Roberto Lima","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2023.03.007_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1590\/S0365-05962009000100006","article-title":"Vitiligo e emo\u00e7\u00f5es","volume":"84","author":"Nogueira","year":"2009","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0010","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Vitiligo Global Issue Consensus Conference Panelists (2012). Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.abd.2023.03.007_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-016-0490-y","article-title":"Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL)","volume":"14","author":"Hedayat","year":"2016","journal-title":"Health Qual Life Outcomes."},{"key":"10.1016\/j.abd.2023.03.007_bib0020","first-page":"526","article-title":"Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes","volume":"44","author":"Shajil","year":"2006","journal-title":"Indian J Exp Biol."},{"key":"10.1016\/j.abd.2023.03.007_bib0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology."},{"key":"10.1016\/j.abd.2023.03.007_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0035","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol."},{"key":"10.1016\/j.abd.2023.03.007_bib0040","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0190-9622(96)90718-5","article-title":"Segmental vitiligo: clinical findings in 208 patients","volume":"35","author":"Hann","year":"1996","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","article-title":"Prevalence of Vitiligo among adults in the United States","volume":"158","author":"Gandhi","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.det.2011.11.013","article-title":"Quality-of-life issues in vitiligo","volume":"30","author":"Bhandarkar","year":"2012","journal-title":"Dermatol Clin."},{"key":"10.1016\/j.abd.2023.03.007_bib0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4274\/balkanmedj.2016.1005","article-title":"Increased risk of metabolic syndrome in patients with Vitiligo","volume":"34","author":"Ata\u015f","year":"2017","journal-title":"Balkan Med J."},{"key":"10.1016\/j.abd.2023.03.007_bib0060","doi-asserted-by":"crossref","first-page":"468","DOI":"10.5114\/ada.2017.71114","article-title":"Neutrophil to lymphocyte ratio in patients with vitiligo","volume":"34","author":"Solak","year":"2017","journal-title":"Postepy Dermatol Alergol."},{"key":"10.1016\/j.abd.2023.03.007_bib0065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0738-081X(97)00126-0","article-title":"Immune mechanisms in vitiligo","volume":"15","author":"Bystryn","year":"1997","journal-title":"Clin Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0070","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0190-9622(86)70260-0","article-title":"Correlation between vitiligo antibodies and extent of depigmentation in vitiligo","volume":"15","author":"Naughton","year":"1986","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.abd.2023.03.007_bib0080","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00403-021-02228-9","article-title":"Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome","volume":"314","author":"El-Domyati","year":"2022","journal-title":"Arch Dermatol Res."},{"key":"10.1016\/j.abd.2023.03.007_bib0085","first-page":"27","article-title":"Chemokines in Vitiligo Pathogenesis: CXCL10 and 12","volume":"14","author":"Gharib","year":"2021","journal-title":"J Clin Aesthet Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0090","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","article-title":"Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo","volume":"83","author":"Wankowicz-Kalinska","year":"2003","journal-title":"Lab Invest."},{"key":"10.1016\/j.abd.2023.03.007_bib0095","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/jid.2012.17","article-title":"Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse","volume":"132","author":"McPhee","year":"2012","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0100","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: a pivotal role of CD8+ Cytotoxic T Lymphocytes in Vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.abd.2023.03.007_bib0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/1346-8138.14004","article-title":"Role of chemokines and the corresponding receptors in vitiligo: a pilot study","volume":"45","author":"Yang","year":"2018","journal-title":"J Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0110","first-page":"81","article-title":"Vitiligo Extent Tensity Index (VETI) score: a new definition, assessment and treatment evaluation criteria in vitiligo","volume":"4","author":"Feily","year":"2014","journal-title":"Dermatol Pract Concept."},{"key":"10.1016\/j.abd.2023.03.007_bib0115","article-title":"The Prevalence of Vitiligo: a meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.abd.2023.03.007_bib0120","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1346-8138.1999.tb02067.x","article-title":"Vitiligo: clinical findings in 1436 patients","volume":"26","author":"Handa","year":"1999","journal-title":"J Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2005.10.001","article-title":"The genetics of generalized vitiligo and associated autoimmune diseases","volume":"41","author":"Spritz","year":"2006","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.abd.2023.03.007_bib0130","first-page":"265","article-title":"Evaluation of sunscreen use patterns in vitiligo patients","volume":"2","author":"Cerci","year":"2010","journal-title":"Surg Cosmet Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0135","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","article-title":"Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families","volume":"16","author":"Alkhateeb","year":"2003","journal-title":"Pigment Cell Res."},{"key":"10.1016\/j.abd.2023.03.007_bib0140","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clindermatol.2013.11.011","article-title":"Vitiligo as a systemic disease","volume":"32","author":"Lotti","year":"2014","journal-title":"Clin Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0145","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2340\/00015555-1141","article-title":"Insulin resistance is increased in patients with vitiligo","volume":"91","author":"Karadag","year":"2011","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.abd.2023.03.007_bib0150","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1365-2133.2000.03801.x","article-title":"Acanthosis nigricans with vitiligo and insulin resistance","volume":"143","author":"Harman","year":"2000","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0155","first-page":"105","article-title":"Cutaneous manifestation of diabetes mellitus","volume":"69","author":"Mahajan","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"10.1016\/j.abd.2023.03.007_bib0160","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/archderm.144.3.310","article-title":"A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases","volume":"144","author":"Birlea","year":"2008","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1758-5996-4-15","article-title":"The skin function: a factor of anti-metabolic syndrome","volume":"4","author":"Zhou","year":"2012","journal-title":"Diabetol Metab Syndr."},{"key":"10.1016\/j.abd.2023.03.007_bib0170","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fimmu.2018.00430","article-title":"C-Reactive Protein in Atherothrombosis and Angiogenesis","volume":"9","author":"Badimon","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.abd.2023.03.007_bib0175","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0180","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/ijd.12160","article-title":"Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo","volume":"53","author":"Abdallah","year":"2014","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0185","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jocd.12517","article-title":"Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-\u03b1) in vitiligo-New insight into pathogenesis of disease","volume":"18","author":"Sushama","year":"2019","journal-title":"J Cosmet Dermatol."},{"key":"10.1016\/j.abd.2023.03.007_bib0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus Kinase Inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.abd.2023.03.007_bib0195","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1203475419833609","article-title":"The Use of Janus Kinase Inhibitors in vitiligo: a review of the literature","volume":"23","author":"Relke","year":"2019","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.abd.2023.03.007_bib0200","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3892\/etm.2021.10229","article-title":"Updates and new medical treatments for vitiligo (Review)","volume":"22","author":"Kubelis-L\u00f3pez","year":"2021","journal-title":"Exp Ther Med."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623002350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623002350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:00:50Z","timestamp":1747652450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059623002350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0365059623002350"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2023.03.007","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical profile of vitiligo patients and relationship with immuno-inflammatory markers","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedade Brasileira de Dermatologia.","name":"copyright","label":"Copyright"}]}}